News

Published on 11 Sep 2022 on Simply Wall St. via Yahoo Finance

EyePoint Pharmaceuticals (NASDAQ:EYPT) Has Debt But No Earnings; Should You Worry?


Article preview image

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. As with many other companies EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) makes use of debt. But the more important question is: how much risk is that debt creating?

What Risk Does Debt Bring?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

NASDAQ.EYPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By...

One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - they ...

Simply Wall St. via Yahoo Finance 9 Mar 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePo...

Insider Monkey via Yahoo Finance 8 Mar 2024

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

Total Net Revenue: Increased to $14.0 million in Q4 2023 from $10.5 million in Q4 2022.Net Produc...

GuruFocus.com via Yahoo Finance 7 Mar 2024

EyePoint Pharmaceuticals appoints new Chief Medical Officer

EyePoint Pharmaceuticals appoints new Chief Medical Officer

Investing.com 4 Mar 2024

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares

On January 26, 2024, David Jones, SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc ...

GuruFocus.com via Yahoo Finance 28 Jan 2024

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 71% Above Its Share...

Key Insights The projected fair value for EyePoint Pharmaceuticals is US$38.94 based on 2 Stage F...

Simply Wall St. via Yahoo Finance 14 Jan 2024

EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), a specialty pharmaceutical company, focuses on develo...

GuruFocus.com via Yahoo Finance 11 Jan 2024

What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling You

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders would be excited to see that the share ...

Simply Wall St. via Yahoo Finance 18 Dec 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders t...

Simply Wall St. via Yahoo Finance 13 Dec 2023

Institutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43%...

Key Insights Institutions' substantial holdings in EyePoint Pharmaceuticals implies that they hav...

Simply Wall St. via Yahoo Finance 11 Dec 2023